These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 5349009)

  • 1. Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas.
    Hellström I; Hellström KE
    Int J Cancer; 1969 Sep; 4(5):587-600. PubMed ID: 5349009
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative in vitro sensitivity of twom methylcholanthrene-induced murine sarcoma lines to humoral and cellular immune cytotoxicity.
    Bataillon G; Pross H; Klein G
    Int J Cancer; 1975 Aug; 16(2):255-65. PubMed ID: 1150353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific killing of tumor cells in vitro in the presence of normal lymphoid cells and sera from hosts immune to the tumor antigens.
    Pollack S; Heppner G; Brawn RJ; Nelson K
    Int J Cancer; 1972 Mar; 9(2):316-23. PubMed ID: 5041610
    [No Abstract]   [Full Text] [Related]  

  • 4. Cell-mediated reactivity to antigens shared by Moloney-virus-induced lymphomas (LSTRA) and certain 3-methylcholanthrene-induced mouse sarcomas.
    Hellström I; Hellström KE; Zeidman L; Bernstein ID; Brown JP
    Int J Cancer; 1979 Apr; 23(4):555-64. PubMed ID: 86527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A microassay for humoral cytotoxicity demonstrating sublethal effects of antibody.
    Cleveland PH; McKhann CF; Johnson K; Nelson S
    Int J Cancer; 1974 Sep; 14(3):417-26. PubMed ID: 4459274
    [No Abstract]   [Full Text] [Related]  

  • 6. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes.
    Sjögren HO; Hellström I; Bansal SC; Hellström KE
    Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1372-5. PubMed ID: 5288389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for two factors in sera of tumor-immunized mice which induce specific lymphoid cell-dependent cytotoxicity: IgG2 and a rapidly appearing factor not associated with IgG or IgM.
    Pollack SB; Nelson K
    Int J Cancer; 1975 Aug; 16(2):339-46. PubMed ID: 1150357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific "arming" of normal lymph-node cells by sera from tumor-bearing mice.
    Pollack S
    Int J Cancer; 1973 Jan; 11(1):138-42. PubMed ID: 4790833
    [No Abstract]   [Full Text] [Related]  

  • 9. Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas.
    Hellström I; Hellström KE
    Int J Cancer; 1970 Mar; 5(2):195-201. PubMed ID: 5449160
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunologic characterization of sarcomas artificially infected with Graffi leukemia virus. II. Studies on the differentiation between viral and new cellular antigens].
    Pasternak L; Pasternak G
    Arch Geschwulstforsch; 1968; 32(4):301-8. PubMed ID: 4308111
    [No Abstract]   [Full Text] [Related]  

  • 11. Suppression of in vitro lymphocyte stimulation in mice bearing primary Moloney sarcoma virus-induced tumors.
    Kirchner H; Herberman RB; Glaser M; Lavrin DH
    Cell Immunol; 1974 Jul; 13(1):32-40. PubMed ID: 4615809
    [No Abstract]   [Full Text] [Related]  

  • 12. Increased tumorigenesis of murine sarcoma virus (Moloney) by coinfection with Rauscher virus or by treatment with antilymphocyte serum.
    Hook WA; Chirigos MA; Chan SP
    Cancer Res; 1969 May; 29(5):1008-12. PubMed ID: 5781092
    [No Abstract]   [Full Text] [Related]  

  • 13. The lymphocyte response to primary Moloney sarcoma virus tumors: definition of a non-specific component of the in vitro cellular hyporeactivity of tumor-bearing hosts.
    Kiessling R; Bataillon G; Lamon EW; Klein E
    Int J Cancer; 1974 Nov; 14(5):642-8. PubMed ID: 4459279
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody-induced redistribution of normal and tumor associated surface antigens.
    Yefenof E; Klein G
    Exp Cell Res; 1974 Oct; 88(2):217-24. PubMed ID: 4372068
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of antibody to theta antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus.
    Herberman RB; Nunn ME; Lavrin DH; Asofsky R
    J Natl Cancer Inst; 1973 Nov; 51(5):1509-12. PubMed ID: 4543478
    [No Abstract]   [Full Text] [Related]  

  • 16. Decrease of cytotoxic immune lymphoid cells following regression of virus-induced sarcomas in mice.
    Levy JP; Lechlerc JC; Gomard E; Pavie J; Kourilsky F
    Bibl Haematol; 1973; 39():689-97. PubMed ID: 4798253
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies on Murine Sarcoma Virus: antigenic characterization of Murine Sarcoma Virus induced tumor cells.
    Chuat JC; Berman L; Gunvén P; Klein E
    Int J Cancer; 1969 Jul; 4(4):465-79. PubMed ID: 4899685
    [No Abstract]   [Full Text] [Related]  

  • 18. An analysis of variables affecting the measurement of tumor immunity in vitro with 125I-iododeoxyuridine-labelled target cells. Studies of immunity to primary Moloney sarcomas.
    Seeger RC; Rayner SA; Owen JJ
    Int J Cancer; 1974 May; 13(5):697-713. PubMed ID: 4367342
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum mediated inhibition of cellular immunity to methylcholanthrene-induced murine sarcomas.
    Hellström I; Hellström KE; Sjögren HO
    Cell Immunol; 1970 May; 1(1):18-30. PubMed ID: 5523573
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens.
    Hellström I; Hellström KE; Evans CA; Heppner GH; Pierce GE; Yang JP
    Proc Natl Acad Sci U S A; 1969 Feb; 62(2):362-8. PubMed ID: 5256215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.